Cancer
Malignant Colon Neoplasm
CI-CAN-00007995Explore in graph →
Top-level225 active trials5 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007995Explore in graph →
Clinical trials
1,196 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (139)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05231850 | A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI. | not yet recruiting | Phase 2 | 70 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Feb 9, 2022 | clinicaltrials |
| NCT00193219 | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 36 | SCRI Development Innovations, LLCOTHER | 1 | Jan 11, 2022 |
| clinicaltrials |
| NCT03661047 | OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer(OMICC) | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Nov 17, 2021 | clinicaltrials |
| NCT01505166 | Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases(FANG-CLM) | terminated | Phase 2 | 3 | Gradalis, Inc.INDUSTRY | 1 | Nov 1, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT04969029 | Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT01902953 | Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC) | completed | Phase 2 | 16 | Maimonides Medical CenterOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT03329664 | Autologous Killer Cell Therapy in Colon Cancer Patients | unknown | Phase 1 / Phase 2 | 20 | Sabz BiomedicalsINDUSTRY | 1 | Mar 15, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT04775862 | A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer. | unknown | Phase 2 | 60 | National Guard Health AffairsOTHER_GOV | 1 | Mar 1, 2021 | clinicaltrials |
| NCT04737213 | SGM-101 in Colorectal Lung Metastases(SGM-CLM) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04475159 | Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial | unknown | Phase 2 | 50 | Prof. Aviram NissanOTHER_GOV | 0 | Jul 17, 2020 | clinicaltrials |
| NCT01363843 | Complete Neoadjuvant Treatment for REctal Cancer (CONTRE) | completed | Phase 2 | 39 | William Sikov MDOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04389151 | Triplezumab Combined With CAPEOX Regimen in Neoadjuvant Therapy for Locally Advanced Colon Cancer | unknown | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | May 15, 2020 | clinicaltrials |
| NCT01744340 | A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer | completed | Phase 1 / Phase 2 | 23 | howard safranOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX | terminated | Phase 2 | 24 | US Oncology ResearchINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT04188158 | Analysis of the Effectiveness of Neoadjuvant Chemotherapy in the Treatment of Colon Cancer Locally Advanced (ELECLA)(ELECLA) | unknown | Phase 2 | 238 | Universidad de LeónOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01802320 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT01111604 | A Study of Ramucirumab or Icrucumab in Colorectal Cancer | completed | Phase 2 | 158 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 6, 2019 | clinicaltrials |
| NCT04035096 | The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients | unknown | Phase 1 / Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT02973672 | Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas | completed | Phase 1 / Phase 2 | 75 | SurgimabINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01985763 | Genistein in Treatment of Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 13 | Sofya PintovaOTHER | 1 | May 10, 2019 | clinicaltrials |
| NCT01206530 | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | completed | Phase 1 / Phase 2 | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT00645710 | Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery | completed | Phase 1 / Phase 2 | 16 | City of Hope Medical CenterOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT02402036 | A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer | terminated | Phase 2 | 10 | Georgetown UniversityOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT00257322 | Cellular Immune Augmentation in Colon and Rectal Cancer | completed | Phase 2 | 20 | University of California, IrvineOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00094809 | Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer | completed | Phase 2 | 252 | AmgenINDUSTRY | 0 | Oct 17, 2018 | clinicaltrials |
| NCT00418938 | SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | completed | Phase 2 | 266 | AmgenINDUSTRY | 0 | Oct 17, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT02216149 | Effects of S-1 and Capecitabine on Coronary Artery Blood Flow(FluoHeart) | terminated | Phase 2 | 20 | Heikki JoensuuOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT02526836 | Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer | unknown | Phase 2 / Phase 3 | 40 | Mansoura UniversityOTHER | 2 | Aug 16, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT00845039 | A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab(FC-4) | terminated | Phase 2 | 4 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00398879 | Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients | completed | Phase 2 | 381 | AEterna ZentarisINDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01462513 | L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases(LICC) | completed | Phase 2 | 122 | Prof. Dr. Carl SchimanskiOTHER | 2 | Feb 13, 2018 | clinicaltrials |
| NCT01729923 | A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer(ADAPT) | terminated | Phase 2 | 27 | University of WashingtonOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT01606124 | Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer | terminated | Phase 2 | 39 | Mayo ClinicOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT02618356 | Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer | unknown | Phase 2 | 82 | Fudan UniversityOTHER | 1 | Oct 2, 2017 | clinicaltrials |
| NCT00003485 | Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer | terminated | Phase 2 | 15 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00468910 | Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer | completed | Phase 2 | 79 | National Cancer Institute (NCI)NIH | 1 | May 31, 2017 | clinicaltrials |
| NCT01292356 | Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response | completed | Phase 2 | 28 | Poitiers University HospitalOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Feb 9, 2022source: clinicaltrials